Abstract | OBJECTIVE: METHODS: RESULTS: The mean blood loss estimated was significantly lower in misoprostol group compared to oxytocin group (819 ml versus 974 ml; p = 0.004). The number of women who had blood loss exceeding 500 ml and the change in hemoglobin, however, was comparable between the two groups. There was a need for additional oxytocic therapy in 16% and 18% after use of misoprostol and oxytocin respectively (p = 0.673). The incidence of side effects such as pyrexia, shivering and metallic taste was significantly higher in misoprostol group compared to oxytocin group. CONCLUSION:
|
Authors | N Vimala, S Mittal, S Kumar |
Journal | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
(Int J Gynaecol Obstet)
Vol. 92
Issue 2
Pg. 106-10
(Feb 2006)
ISSN: 0020-7292 [Print] United States |
PMID | 16343498
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Oxytocics
- Misoprostol
- Oxytocin
|
Topics |
- Administration, Sublingual
- Adult
- Cesarean Section
(adverse effects)
- Female
- Humans
- Infusions, Intravenous
- Misoprostol
(administration & dosage, adverse effects, therapeutic use)
- Oxytocics
(administration & dosage, adverse effects, therapeutic use)
- Oxytocin
(administration & dosage, adverse effects, therapeutic use)
- Postpartum Hemorrhage
(prevention & control)
- Pregnancy
- Treatment Outcome
|